Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Armata Pharmaceuticals, Inc.

NYSE: ARMP · Life Sciences · 4 alerts · CIK 921114

Share price
$2.99Close, Nov 16
Market cap
$111M
Shares outstanding
37.19MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Armata Pharmaceuticals, Inc. filings on SEC EDGAR ↗

4:24 PM ET 8-K
Financial Results

Armata Pharmaceuticals Financial Results

Armata Pharmaceuticals reported its third quarter 2026 financial results and provided an update on its AP-SA02 Phase 3 program. The company is finalizing study designs with the FDA and has completed engineering runs at its cGMP manufacturing facility to support the upcoming pivotal trial.

“We continue to advance toward our most important near-term objective: initiating the Phase 3 superiority study of AP-SA02. We have progressed from planning to establishing the operational infrastructure needed to execute a large, pivotal clinical study.”

Dr. Deborah Birx, Chief Executive Officer

“We believe the FDA’s recent Breakthrough Therapy designation further underscores AP-SA02’s clinical potential. We also appreciate the continued financial support of the U.S. Department of War (“DoW”), which comes at an important time as we prepare for this next critical stage of clinical development.”

Dr. Deborah Birx, Chief Executive Officer
7:11 AM ET 8-K
Business Update

Armata Pharmaceuticals Business Update

Armata Pharmaceuticals received $3.7 million in additional non-dilutive funding from the U.S. Department of War to support the Phase 3 development of its AP-SA02 bacteriophage candidate. This incremental funding brings the total cumulative government support for the program to $32.4 million and is intended to fund activities for a pivotal superiority study in complicated S. aureus bacteremia.

Counterparty
U.S. Department of War

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.